Results 131 to 140 of about 2,891 (162)

Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance

Cell Reports, 2022
Julhash U Kazi, Jesper Olsen, Caroline Wigerup   +2 more
exaly  

Pembrolizumab/selinexor

Reactions Weekly, 2021
openaire   +1 more source

Drug resistance biomarker ABCC4 of selinexor and immune feature in multiple myeloma

International Immunopharmacology, 2022
Yang Liang, Yu-Jun Dai, Xiao-Qin Chen
exaly  

Selinexor

Reactions Weekly, 2018
openaire   +1 more source

Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies

Gynecologic Oncology, 2020
Els Van Nieuwenhuysen, Sileny Han, Nicole Concin   +2 more
exaly  

The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review

Journal of Cancer Research and Clinical Oncology, 2022
, Jennifer Landes, Peter L Rady
exaly  

Decitabine/selinexor/tucidinostat

Reactions Weekly, 2023
openaire   +1 more source

Selinexor for Refractory Multiple Myeloma

New England Journal of Medicine, 2019
Kenar D, Jhaveri, Rimda, Wanchoo
openaire   +2 more sources

Selinexor

Reactions Weekly
openaire   +2 more sources

Bortezomib/dexamethasone/selinexor

Reactions Weekly, 2022
openaire   +1 more source